Consolidated cash flow statements
(unaudited)
|
Nine months ended 30 September |
|
(thousands of €) |
2019 |
2018 |
Net profit / loss (–) of the period |
265,329 |
(44,215) |
|
|
|
Adjustment for non-cash transactions |
151,366 |
16,278 |
Adjustment for items to disclose separately under operating cash flow |
(23,432) |
(2,887) |
Adjustment for items to disclose under investing and financing cash flows |
(3) |
3 |
Change in working capital other than deferred income |
41,127 |
27,053 |
Increase / decrease (–) in deferred income |
2,890,286 |
(93,370) |
|
|
|
Cash generated / used (–) in operations |
3,324,674 |
(97,137) |
|
|
|
Interest paid |
(901) |
(1,026) |
Interest received |
5,129 |
3,252 |
Corporate taxes paid |
(145) |
(7) |
|
|
|
Net cash flows generated / used (–) in operating activities |
3,328,758 |
(94,918) |
|
|
|
Purchase of property, plant and equipment |
(17,322) |
(4,259) |
Purchase of intangible fixed assets |
(5,465) |
(1,533) |
Proceeds from disposal of property, plant and equipment |
1 |
1 |
Acquisition of financial assets held at fair value through profit or loss |
(177) |
– |
Proceeds from sale of financial assets held at fair value through profit or loss |
82 |
134 |
|
|
|
Net cash flows used in investing activities |
(22,881) |
(5,657) |
|
|
|
Payment of lease liabilities |
(3,834) |
(6) |
Proceeds from capital and share premium increases, gross amount |
960,087 |
296,188 |
Issue costs paid related to capital and share premium increases |
– |
(15,008) |
Proceeds from capital and share premium increases from exercise of warrants |
14,480 |
5,261 |
|
|
|
Net cash flows generated in financing activities |
970,733 |
286,435 |
|
|
|
Increase in cash and cash equivalents |
4,276,610 |
185,860 |
|
|
|
Cash and cash equivalents at beginning of the period |
1,290,796 |
1,151,211 |
|
|
|
Increase in cash and cash equivalents |
4,276,610 |
185,860 |
|
|
|
Effect of exchange rate differences on cash and cash equivalents |
32,380 |
6,596 |
|
|
|
Cash and cash equivalents at end of the period |
5,599,787 |
1,343,668 |
The accompanying notes form an integral part of these condensed consolidated financial statements.